Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12951MR)

This product GTTS-WQ12951MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12951MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6716MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ14914MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11642MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ100MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ5966MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ13961MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13179MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW